ZIMVV ZIMVIE INC

ZimVie Announces FDA Clearance and U.S. Launch of GenTek® Restorative Components

ZimVie Announces FDA Clearance and U.S. Launch of GenTek® Restorative Components

Addition of Premium Restorative Components Enhances ZimVie’s End-to-End Implant Offerings

PALM BEACH GARDENS, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced the U.S. launch of its GenTek® Genuine Restorative Components product portfolio. The launch expands ZimVie’s portfolio of end-to-end prosthetic offerings and follows the recent receipt of FDA 510(k) clearance. ZimVie first launched the GenTek portfolio in Europe in 2019 and has seen tremendous success in that market to date.

The introduction of GenTek to the U.S. market brings a broad offering of differentiated restorative components to the ZimVie product family. The GenTek restorative portfolio is comprised of Ti-Bases, pre-milled abutment blanks, screws, instruments, and ancillary products to support digitally driven CAD/CAM restorations. Manufactured and designed to mate with ZimVie implant systems, the genuine connection* ensures a perfect fit and tight seal to support long-term aesthetic and functional restorations.

“We’re excited to expand our product portfolio with the introduction of GenTek premium prosthetic components, enabling digital workflows and patient-specific restorations for U.S. customers,” said Indraneel Kanaglekar, SVP, Chief Commercial Officer. “We have received excellent feedback and strong demand for GenTek in the European market, and we are optimistic that this product suite will be well received here in the U.S. – the largest market we serve.”

.

About GenTek®

Genuine connection components are designed and manufactured to minimize the micro-gaps and micro-movements for a robust and stable interface between the implant and abutment. GenTek CEREC® compatible (Sirona inCoris Meso Block) and angulated screw channel Ti-Bases, pre-milled abutment blanks, and scan bodies are part of a complete and open digital workflow. Products are available for ZimVie’s TSX®/ TSV®/Trabecular Metal®, T3® PRO/Certain®, and Eztetic® Dental Implant Systems.

For more information on our GenTek portfolio, visit .

For more information on ZimVie Dental implants, suite of connected solutions, and continuing education, please visit .

*GenTek is manufactured by Zfx GmbH, a subsidiary of ZimVie.

About ZimVie

ZimVie is a global life sciences leader in the dental market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at . Follow @ZimVie on , , , or .

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning ZimVie’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs, expectations, and assumptions of management and are subject to significant risks, uncertainties, and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. For a list and description of some of such risks and uncertainties, see ZimVie’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in ZimVie’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and ZimVie disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Readers of this press release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary note is applicable to all forward-looking statements contained in this press release.

Media Contact Information:

ZimVie

Allison Johnson •

(774) 266-8046

ZimVie

Grace Flowers •

(561) 319-6130

Investor Contact Information:

Gilmartin Group LLC

Marissa Bych •



EN
23/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZIMVIE INC

 PRESS RELEASE

ZimVie Announces Completion of its Acquisition by ARCHIMED

ZimVie Announces Completion of its Acquisition by ARCHIMED ZimVie Inc. Becomes Privately Held Company PALM BEACH GARDENS, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (“ZimVie”), a global life sciences leader in the dental implant market, today announced that ARCHIMED, an investment firm focused exclusively on healthcare industries, has completed its previously announced acquisition of ZimVie. Pursuant to the terms of the transaction announced on July 20, 2025, ARCHIMED acquired all of the outstanding shares of ZimVie stock. ZimVie stockholders are entitled to receive $19.00 in ...

 PRESS RELEASE

ZimVie Stockholders Vote to Approve Acquisition by ARCHIMED

ZimVie Stockholders Vote to Approve Acquisition by ARCHIMED PALM BEACH GARDENS, Fla., Oct. 10, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (“ZimVie”) (Nasdaq: ZIMV) today announced that at the special meeting of ZimVie stockholders held on October 10, 2025, the ZimVie stockholders voted to approve the acquisition of ZimVie by an affiliate of ARCHIMED (the “Merger”) pursuant to the terms and conditions of the Agreement and Plan of Merger, dated as of July 20, 2025 (the “Merger Agreement”). The parties now expect the Merger to close on October 20, 2025, subject to the satisfaction of all conditio...

 PRESS RELEASE

ZimVie Reports Second Quarter 2025 Financial Results

ZimVie Reports Second Quarter 2025 Financial Results Recently entered into definitive agreement to be acquired by ARCHIMED for $19.00 in cash per shareNet Sales from Continuing Operations of $116.7 millionNet Loss from Continuing Operations of $(3.8) million; Net Loss margin of (3.3)% Adjusted EBITDA[1] from Continuing Operations of $17.5 million; Adjusted EBITDA[1] margin of 15.0%GAAP diluted EPS from Continuing Operations of $(0.14) and adjusted diluted EPS[1] from Continuing Operations of $0.26 PALM BEACH GARDENS, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a g...

 PRESS RELEASE

ZimVie to Report Second Quarter 2025 Financial Results on July 30, 202...

ZimVie to Report Second Quarter 2025 Financial Results on July 30, 2025 PALM BEACH GARDENS, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced it will report financial results for the second quarter 2025 and file its Quarterly Report on Form 10-Q after market close on Wednesday, July 30, 2025. On July 21, 2025, ZimVie issued a press release announcing ZimVie’s entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED (“ARCHIMED”) for $19.00 in cash pe...

 PRESS RELEASE

ZimVie Announces Exclusive Distribution Agreement with Osstem Implant ...

ZimVie Announces Exclusive Distribution Agreement with Osstem Implant to Expand Premium Dental Implant Offering in China Strategic Partnership Provides Market Presence in Growing Chinese Market PALM BEACH GARDENS, Fla., July 23, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced a strategic distribution agreement with Osstem Implant Co., Ltd. (“Osstem Implant”), a leading dental solutions provider specializing in high-quality implants and integrated dental technologies globally. The agreement expands ZimVie’s ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch